RecruitingRecruiting
Residual Exacerbations With Mepolizumab
NCT04578171 · Laval University
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Type and Mechanisms of Residual Asthma Exacerbations in Patients Treated With Mepolizumab
About this study
Before initiation of mepolizumab, a recording of patient's demographics, clinical, physiological and inflammatory features will be recorded. All subjects will be reassessed for the above measures at 6, 12, 18 and 24 months.
In addition to the above visits, patients will be assessed every time they experience either moderate or severe exacerbation of asthma over the treatment period.
Based on the percentage of sputum eosinophils and neutrophils, the type of inflammatory exacerbation will be determined
Eligibility criteria
Inclusion Criteria:
* With a proven diagnosis of severe asthma as defined by the Canadian Thoracic Society
* Eligible for mepolizumab treatment
* Able and willing to sign the informed consent form
Exclusion Criteria:
* Any respiratory disease apart from asthma
* Confounding comorbidities sur as eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome
Study design
Enrollment target: 60 participants
Age groups: adult, older_adult
Timeline
Starts: 2021-07-06
Estimated completion: 2028-01
Last updated: 2025-02-10
Interventions
Drug: Mepolizumab
Primary outcomes
- • Proportion of eosinophilic vs non-eosinophilic remaining exacerbation during the treatment period (Between baseline and month 24)
Sponsor
Laval University · other
With: GlaxoSmithKline
Contacts & investigators
ContactMarie-Eve Boulay, MSc · contact · marie-eve.boulay@criucpq.ulaval.ca · 4186568711
InvestigatorAndréanne Côté, MD · principal_investigator, IUCPQ-UL
All locations (1)
Institut universitaire de cardiologie et de pneumologie de QuébecRecruiting
Québec, Quebec, Canada